Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 6/20 | 0.35 |
| ▸ | NOS3 | P29474 | 5/20 | 0.35 |
| ▸ | NOS1 | P29475 | 5/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25955544 | 0.85 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL791473 | 0.82 | NOS2 (0.40) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL24207669 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL23634822 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL24207502 | 0.76 | NOS2 (0.38) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL18685384 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL16803623 | 0.72 | SIGMAR1 (0.39) | KDM4EALDH1A1NOS2SLC6A2SLC6A4 | |
| SCHEMBL14980283 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL13162838 | 0.72 | KDM4E (0.41) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL24204475 | 0.71 | SLC6A2 (0.37) | KDM4EALDH1A1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | KDM4E 1286/4885ALDH1A1 2445/4885NOS2 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.